Healthy
Conditions
Keywords
During, Endoscopy, Gastric, Peristalsis
Brief summary
The purpose of this study is to evaluate the safety and efficacy of the additional administration of scopolamine butylbromide, glucagon or NPO-11 following a single intragastric dose of NPO-11 during endoscopy in healthy adult men. The safety will be evaluated based on adverse events and adverse drug reactions (ADRs) observed with NPO-11 + scopolamine butylbromide or glucagon, and following additional administration of NPO-11. The efficacy will be evaluated based on changes in the frequency of gastric peristalsis classification after the initial dose and the additional dose, and on the presence or absence of gastric peristalsis at each evaluation point.
Interventions
DRUGNPO-11
20 mg butylscopolammonium bromide after administration of NPO-11
Sponsors
Nihon Pharmaceutical Co., Ltd
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
35 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
Healthy adult male volunteers who meet all the following criteria will be enrolled in the study. Subjects have to provide written informed consent for voluntary participation in the study. 1. Volunteers who are in good health as confirmed by the investigator or subinvestigator 2. Volunteers (age from 35 to less than 65 years old at the time of consent)
Exclusion criteria
Volunteers who meet any of the following criteria will be excluded from the study. 1. Volunteers with any clinically significant symptoms, physical findings or laboratory values at screening visit which are considered unsuitable for participation in the study in the investigator's or subinvestigator's opinion 2. Volunteers with a history of surgery in the upper gastrointestinal tract 3. Volunteers with a history of shock or hypersensitivity to l-menthol or peppermint oil (mint oil) 4. Volunteers with a history of shock or hypersensitivity to scopolamine butylbromide, glucagon, lidocaine hydrochloride or heparin sodium 5. Volunteers who are contraindicated for administration of scopolamine butylbromide or glucagon in the investigator's or subinvestigator's opinion based on health interview 6. Volunteers who have been exposed to NPO-11 7. Volunteers who have received other investigational drugs within four months before consent or who are participating in other clinical studies 8. Volunteers otherwise ineligible for participation in the study in the investigator's or subinvestigator's opinion
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| [Safety] (Evaluation by investigator or subinvestigator) Adverse events and ADRs observed between administration and 7 ± 3 days after administration | 7 ± 3 days after administration |
Secondary
| Measure | Time frame |
|---|---|
| [Efficacy] (Central evaluation by independent evaluator) (1) Change in the frequency of gastric peristalsis classification (2) Presence or absence of gastric peristalsis at each evaluation point | each evaluation point |
Countries
Japan
Outcome results
None listed